



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 October 2022
EMA/68003/2022
Press office

Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 10-13 October 2022

During its October 2022 meeting, the CHMP reviewed 1 recommendation for eligibility to PRIME: 1 was granted.
The individual outcome adopted this month is listed below.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Eligibility granted

Name*	Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Nicardipine	Chemical Medicinal Product	Neurology	Treatment of non-traumatic subarachnoid haemorrhage in patients undergoing surgery	Nonclinical + Clinical exploratory	SME


* Name of the active substance, INN, common name, chemical name or company code.

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

Cumulative overview of PRIME eligibility recommendations adopted by 13 October 2022


■ Granted ■ Denied ■ Out of scope* ■ Withdrawn

Overall number




■ Granted ■ Denied ■ Out of scope* ■ Withdrawn

By Applicant Type



By therapeutic area



* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.